Zhongshan Hospital Xiamen University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website: http://www.xmzsh.com

Clinical Trials

Exploring the Risk Factors of Otomycosis: A Case-Control Study

Recruiting

Conditions: Otomycosis

Interventions: Other: exposures

First Posted Date: 2024-07-31

Last Posted Date: 2024-08-09

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 200

Registration Number: NCT06530069

Locations: 🇨🇳
Zhongshan Hospital of Xiamen university, Xiamen, Fujian, China

Efficacy of Self vs. Physician Application of Triamcinolone-Econazole in Otomycosis

Phase 4

Completed

Conditions: Otomycosis

Interventions: Procedure: physician-applied Triamcinolone Acetonide Econazole Cream
Procedure: patient-applied Triamcinolone Acetonide Econazole Cream

First Posted Date: 2024-05-28

Last Posted Date: 2024-11-01

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 200

Registration Number: NCT06431542

Locations: 🇨🇳
Xiamen University Zhongshan Hospital, Xiamen, Fujian, China

Effect of Carbon Dioxide Insufflation and Appendix on the Restoration of Intestinal Microecology After Colonoscopy.

Active, not recruiting

Conditions: Colonoscopy
Gastrointestinal Microbiome
Carbon Dioxide Insufflation
Appendix

Interventions: Other: Carbon dioxide insufflated during colonoscopy

First Posted Date: 2022-12-05

Last Posted Date: 2022-12-09

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 38

Registration Number: NCT05637021

Locations: 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Phase 2

Conditions: Stage IV Gastric Cancer With Metastasis

Interventions: Drug: Camrelizumab; Nab-paclitaxel; S-1

First Posted Date: 2022-07-01

Last Posted Date: 2022-07-08

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 33

Registration Number: NCT05441254

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Phase 2

Conditions: Solid Tumor

Interventions: Drug: Pyrotinib Maleate
Other: standard regimen

First Posted Date: 2022-03-10

Last Posted Date: 2022-03-10

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 60

Registration Number: NCT05274191

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.

Phase 4

Conditions: Thyroid Cancer, Papillary
Hypothyroidism

Interventions: Drug: L-T4+T3 (thyroid tablet)
Drug: L-T4

First Posted Date: 2022-02-18

Last Posted Date: 2022-02-18

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 50

Registration Number: NCT05247476

Locations: 🇨🇳
Yan Ling, Xiamen, Fujian, China

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Apatinib Mesylate
Drug: Abraxane
Drug: Cis Platinum
Drug: Carboplatin

First Posted Date: 2020-10-19

Last Posted Date: 2020-10-19

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 58

Registration Number: NCT04590625

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China

A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease

Phase 1

Recruiting

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis Type

Interventions: Drug: fecal microbiota capsule

First Posted Date: 2020-08-20

Last Posted Date: 2023-11-14

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 200

Registration Number: NCT04521205

Locations: 🇨🇳
Yanyun Fan, Xiamen, China

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Phase 1

Conditions: Hepatic Metastasis of Colorectal Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib Mesylate
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: radiofrequency ablation

First Posted Date: 2019-12-18

Last Posted Date: 2020-04-16

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 23

Registration Number: NCT04202978

Locations: 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Phase 4

Conditions: Type 2 Diabetes
Diabetic Nephropathy

Interventions: Drug: SGLT2 Inhibition

First Posted Date: 2019-10-15

Last Posted Date: 2019-10-21

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 70

Registration Number: NCT04127084

Locations: 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy